The central reasons (repeatable pattern across literature): Comparator sensitivity: DPP-4i vs sulfonylureas vs SGLT2i changes results Ascertainment differences: Who gets ultrasounds, when, and why Outcome definition: "Thyroid cancer," "tumors," "neoplasm," and "MTC" aren't interchangeable Short follow-up: Better at capturing diagnostic workups than long-term carcinogenesis Residual confounding: Obesity, diabetes duration, smoking, iodine status, healthcare access When Studies Disagree: It's often because they used different comparison drugs, definitions, and populations watched more closely
Renal and hepatic function
Introduction GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized weight management and type 2 diabetes treatment, helping over 1.6 million adults in England, Wales, and Scotland between early 2024 and early 2025
Is Ozempic or metformin more effective
This creates a flatter pharmacokinetic curve with lower peak levels and higher trough levels, potentially reducing the intensity of receptor desensitization at peak concentrations while maintaining more consistent receptor occupancy throughout the week